Illumina Offers Beat-And-Raise As The Hunt For Covid Variants Intensifies

Illumina (ILMN) offered a beat-and-raise late Thursday as the genetic sequencing giant helps track the spread of Covid variants. But Illumina stock dipped in late action.


During the second quarter, Illumina earned $1.87 per share, minus some items, on $1.13 billion in sales. Earnings popped nearly 202% while sales jumped 78% year over year. Both measures easily topped the average estimate of analysts polled by FactSet for $1.36 and $1.01 billion, respectively.

Revenue exceeded expectations across all geographies, Chief Executive Francis deSouza said in a written statement.

“Additionally, we are proud of the critical role that (next-generation sequencing) plays in identifying and monitoring Covid-19 variants to inform strategies to combat the pandemic,” he said. “As a result of the enduring strength of the core business, we are again raising our 2021 financial guidance.”

For the year, Illumina now expects to earn $6.30-$6.50 per share. The company also called for 32%-34% sales growth, or $4.28 billion to $4.34 billion. Illumina stock analysts expected earnings of $6 per share and $4.16 billion in sales.

In after-hours trading on the stock market today, Illumina stock dipped a fraction near 515. During the regular session, shares ticked up into a buy zone above a buy point at 488.10 out of a cup-with-handle base on the weekly chart, according to

Follow Allison Gatlin on Twitter at @IBD_AGatlin.


Moderna Stock, IBD 50 Stock To Watch, Notches New Record As Earnings Obliterate Forecasts

Regeneron Stock Flirts With Breakout As Covid Drug Beats Views By $1 Billion

Short-Term Trades Can Add Up To Big Profits. IBD’s SwingTrader Shows You How

Want More IBD Insights? Subscribe To Our Investing Podcast!

Find Today’s Best Growth Stocks To Watch With IBD 50

William Murphy

William Murphy

Related post